All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2020-07-14T16:23:34.000Z

An update in CLL from EHA 2020

Jul 14, 2020
Share:

Bookmark this article

During the 25th European Hematology Association (EHA) Annual Congress, the Lymphoma Hub spoke to Susan O'Brien, University of California Irvine, Orange, US, who discussed the latest updates on chronic lymphocytic leukemia (CLL) from EHA 2020.

An update in CLL from EHA 2020

Highlights in CLL from this year's virtual EHA Annual Congress include

  1. Update (~39 months) from the CLL-14 trial (NCT02242942), comparing the safety and efficacy of obinutuzumab + venetoclax versus obinutuzumab + chlorambucil in patients with treatment-naïve CLL
  2. Update from the CAPTIVATE trial (NCT02910583) evaluating ibrutinib + venetoclax in patients with treatment-naïve CLL
  3. Acalabrutinib for the treatment of relapsed CLL

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox